Payment overview · 2025
General Payments
$1,061.47
44 reported records · 10 companies
Healthcare provider profile · identity verified
Amanda Phillips, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MACON, GA · NPI 1306257035
Verified facts
What the public records show
CMS Open Payments records show Amanda Phillips, NP received $1,061.47 in general payments during 2025 across 44 reported records.
Abbott Laboratories accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Verquvo.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1008 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $311.95 | 29.4% | 14 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $278.14 | 26.2% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $146.81 | 13.8% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $99.72 | 9.4% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $92.76 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.25 | 6.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.29 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.97 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.59 | 1.4% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $5.99 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,061.47 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $295.82 | 13 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $278.14 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $115.45 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $99.72 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $92.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.25 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $10.10 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $5.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
256 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1008 | 183 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1427 | 374 |
| Eliquis | Apixaban | 1008 | 183 |
| Amiodarone Hcl | Amiodarone Hcl | 763 | 201 |
| Flecainide Acetate | Flecainide Acetate | 510 | 111 |
| Carvedilol | Carvedilol | 386 | 91 |
| Furosemide | Furosemide | 314 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 77 |
| Entresto | Sacubitril/Valsartan | 256 | 55 |
| Bumetanide | Bumetanide | 228 | 65 |
| Losartan Potassium | Losartan Potassium | 218 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 52 |
| Lisinopril | Lisinopril | 164 | 51 |
| Midodrine Hcl | Midodrine Hcl | 163 | 48 |
| Mexiletine Hcl | Mexiletine Hcl | 161 | 36 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 140 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 136 | 37 |
| Propafenone Hcl | Propafenone Hcl | 130 | 28 |
| Pindolol | Pindolol | 127 | 36 |
| Potassium Chloride | Potassium Chloride | 117 | 31 |
| Propafenone Hcl Er | Propafenone Hcl | 106 | 24 |
| Spironolactone | Spironolactone | 105 | 31 |
| Xarelto | Rivaroxaban | 98 | 28 |
| Farxiga | Dapagliflozin Propanediol | 92 | 17 |
| Ranolazine Er | Ranolazine | 85 | 24 |
| Digoxin | Digoxin | 74 | 19 |
| Sotalol | Sotalol Hcl | 73 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 22 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 62 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 17 |
| Nifedipine Er | Nifedipine | 58 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 12 |
| Dofetilide | Dofetilide | 50 | 12 |
| Propranolol Hcl | Propranolol Hcl | 50 | 15 |
| Multaq | Dronedarone Hcl | 48 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Prazosin Hcl | Prazosin Hcl | 37 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 33 | 13 |
| Acebutolol Hcl | Acebutolol Hcl | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 12 |
| Valsartan | Valsartan | 28 | suppressed |
| Droxidopa | Droxidopa | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Nadolol | Nadolol | 26 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,061.47 · 44 records | Abbott Laboratories | ASSURITY, AVEIR, CAPVAXIVE, General - Therapies, INSPIRE, JETSTREAM SC, Kerendia, LEQVIO, LifeVest, NEXLETOL, RHYTHM EXPRESS, VERQUVO, VYNDAQEL, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Verquvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error